Pharmacogenomics and histone deacetylase inhibitors.

about

Pharmacogenomics and histone deacetylase inhibitors.

Item

http://www.wikidata.org/entity/Q38987332

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Pharmacogenomics and histone deacetylase inhibitors.

@en

type

Item

label

Pharmacogenomics and histone deacetylase inhibitors.

@en

prefLabel

Pharmacogenomics and histone deacetylase inhibitors.

@en

P1476

Pharmacogenomics and histone deacetylase inhibitors.

@en

P2093

Cody J Peer

http://www.w3.org/2001/XMLSchema#string

Tristan M Sissung

http://www.w3.org/2001/XMLSchema#string

William D Figg

http://www.w3.org/2001/XMLSchema#string

P2860

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men

The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.

Impact of ABCB1 allelic variants on QTc interval prolongation.

Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis.

P304

1807-1815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS-2016-0113

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrew K L Goey

P577

2016-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27767376

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

5558504

http://www.w3.org/2001/XMLSchema#string

Pharmacogenomics and histone deacetylase inhibitors.

about

Pharmacogenomics and histone deacetylase inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932